newsfilter
← Latest News
PR Newswire·

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

RNABMY
  • Atrium Therapeutics received a $15 million development milestone payment from Bristol Myers Squibb.
  • The payment was triggered by the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication.
  • The milestone is part of a global licensing & research collaboration focused on discovering & developing RNA-based therapies for cardiovascular indications.
  • Atrium is eligible for up to $1.35 billion in research & development milestone payments, up to $825 million in commercial milestone payments, & tiered royalties on net sales.
  • Bristol Myers Squibb will fund all future clinical development, regulatory, & commercialization activities under the agreement.
  • Atrium's pipeline includes candidates ATR 1072 for PRKAG2 syndrome & ATR 1086 for PLN cardiomyopathy.
  • PRKAG2 syndrome affects 1,000–2,000 people in the US & currently has no approved therapies targeting the underlying genetic driver.
  • PLN cardiomyopathy affects 2,000–4,000 people in the US & currently lacks approved therapies for the molecular cause.
  • Atrium Therapeutics uses a proprietary platform to deliver siRNA therapeutics directly to the heart via non-viral methods.